{"filings":[{"id":1396518,"accession_number":"0001404644-26-000050","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2026-07-02T00:02:10+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Neurogene raises ~$134.8M in public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3.5M shares at $30.00 and pre-funded warrants for 666,666 shares at $29.999999.","Underwriters exercised option for additional 624,999 shares; total net proceeds ~$134.8M.","Offering expected to close July 2, 2026; proceeds plus existing cash fund operations into Q1 2029.","Pre-funded warrants exercisable immediately, subject to 4.99%/9.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1315597,"accession_number":"0001404644-26-000046","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2026-06-29T12:00:50+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Neurogene reports positive Phase 1/2 data for NGN-401 in Rett syndrome; 47 milestones gained across 10 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["47 developmental milestones gained across 10 participants (avg 4.7); 100% improved CGI-I and gained ≥1 milestone.","Durable effect through 30 months with no plateau or milestone loss; median time to first improvement 2 months.","NGN-401 generally well-tolerated; no new treatment-related SAEs since Oct 2025; all AEs mild or moderate.","Dosing complete in Embolden registrational trial; no treatment-related SAEs or DLTs; topline data expected 2H 2027.","Improvements across RSGMS and RSHFS scales (p<0.001); 7/10 gained ≥2 milestones across ≥2 Rett domains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":900356,"accession_number":"0001404644-26-000044","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2026-06-08T11:32:53+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene completes dosing in NGN-401 Rett trial; no HLH, topline expected 2H 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosed 25 participants in Embolden trial (target 20, ITT up to 24) due to strong demand from Rett community.","NGN-401 generally well-tolerated; no HLH cases at 1E15 vg dose across Phase 1/2 and Embolden (n=35).","Topline data from registrational trial expected in 2H 2027; BLA submission planned.","Interim Phase 1/2 data with ≥12-month follow-up for all 10 participants expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":862316,"accession_number":"0001404644-26-000040","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2026-06-04T20:41:02+00:00","items":["5.07"],"status":"ready","headline":"Neurogene stockholders elect directors, approve executive compensation, ratify Deloitte","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors Robert Baffi (9,540,734 for) and Rohan Palekar (10,058,331 for) elected to three-year terms.","Non-binding advisory vote on named executive officer compensation passed: 9,991,445 for, 36,394 against.","Ratification of Deloitte & Touche as auditor for FY 2026 approved: 9,345,925 for, 1,939,039 against.","Advisory vote on frequency of future compensation votes: 10,006,265 chose one year; company will hold votes annually.","Quorum of 11,387,407 shares (72.92%) present; meeting held June 3, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40291,"accession_number":"0001404644-26-000038","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2026-05-12T20:06:30+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurogene reports Q1 net loss $30.9M; ~90% dosed in Rett gene therapy trial, cash runway to Q1 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.9M for Q1 2026 vs $22.6M in Q1 2025; R&D expenses $25.2M driven by NGN-401 trial and CMC costs.","~90% of participants dosed in Embolden registrational trial; on track to complete dosing in Q2 2026; no HLH at 1E15 vg dose.","Cash, equivalents and short-term investments $243.2M as of March 31, 2026; expected to fund operations through Q1 2028.","Appointed Christy Shafer as Chief Commercial Officer; Christine Mikail added to Board of Directors.","Interim Phase 1/2 data with ≥12 months follow-up for all 10 participants expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92659,"accession_number":"0001404644-26-000030","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Neurogene appoints Christy Shafer as CCO, Christine Mikail to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christy Shafer joins as CCO; previously SVP/GM at Avidity Biosciences and CCO at Marinus Pharmaceuticals.","Shafer will lead commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome.","Christine Mikail, President and CFO, appointed to Board as Class II director through 2028 annual meeting.","Mikail brings expertise in strategy, finance, and corporate development; no additional compensation for board role.","Appointments position Neurogene for next phase of growth as it advances NGN-401 toward potential launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103650,"accession_number":"0001404644-26-000012","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurogene reports FY2025 net loss $90.4M, cash $269M; NGN-401 dosing on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $90.4M in FY2025 vs $75.1M in FY2024; cash $269M funds through Q1 2028.","100% enrolled in Embolden registrational trial for Rett syndrome; >50% dosed; on track to complete dosing Q2 2026.","NGN-401 generally well-tolerated at 1E15 vg dose, no HLH cases; FDA Breakthrough Therapy designation granted.","R&D expenses $75.0M up from $60.9M; G&A $28.3M up from $22.6M.","Key milestones: interim Phase 1/2 data mid-2026, PPQ campaign mid-2026, BLA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103649,"accession_number":"0001404644-26-000006","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene's NGN-401 receives FDA Breakthrough Therapy designation for Rett syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy designation for NGN-401, a gene therapy for Rett syndrome.","Designation based on interim Phase 1/2 data showing clinically meaningful, durable multidomain improvements.","Completion of dosing in Embolden registrational trial expected Q2 2026.","Company plans to present additional interim Phase 1/2 data in mid-2026.","NGN-401 also has RMAT, Rare Pediatric Disease designations; part of FDA START Pilot Program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103648,"accession_number":"0001404644-26-000003","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene doses multiple participants in Embolden Rett trial; interim data mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosed multiple participants in Embolden registrational trial in Q4 2025; expect to complete dosing Q2 2026.","Plan to present interim Phase 1/2 data (8 pediatric, 2 adolescent/adult) with >=12-month follow-up mid-2026.","Cash runway through Q1 2028; early commercial-readiness activities underway including payor research.","Initiated 13 U.S. clinical trial sites; presenting at J.P. Morgan Healthcare Conference on Jan 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119915,"accession_number":"0001404644-25-000103","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurogene Q3 2025: $21M net loss; NGN-401 gene therapy shows 35 skill acquisitions, registrational trial started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.0M for Q3 2025 vs $20.2M in Q3 2024; R&D expenses $17.2M, G&A $6.6M.","Positive interim Phase 1/2 data: 35 developmental milestones/skills acquired across 8 pediatric participants; durable CGI-I gains.","First participant dosed in Embolden registrational trial for Rett syndrome; enrollment expected in 3-6 months.","Cash, equivalents, investments of $265.4M as of Sep 30, 2025; runway through Q1 2028.","Preclinical data showed ICV delivery superior to IT-L for AAV biodistribution in key brain regions."],"consensus_eps_estimate":-1.275,"consensus_eps_actual":-3.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119914,"accession_number":"0001404644-25-000098","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene Reports Positive Interim Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 pediatric participants (ages 4-10) showed functional gains across spectrum of disease severity.","35 developmental milestones/skills acquired across hand function, language/communication, and gross motor domains.","NGN-401 at the 1E15 vg dose was generally well-tolerated with no evidence of HLH in any participant.","Gains were durable with continued skill acquisition observed up to 24 months post treatment.","Company to discuss results at Stifel 2025 Healthcare Conference webcast on November 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119913,"accession_number":"0001404644-25-000091","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene doses first participant in Embolden registrational trial of NGN-401 for Rett syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participant dosed in single-arm, open-label, baseline-controlled registrational trial of NGN-401 gene therapy for Rett syndrome.","Trial targets 20 females ages 3+; enrollment expected to complete in 3-6 months.","12 of 13 clinical sites initiated; trial designed to support future BLA submission.","Company to present Phase 1/2 interim data at Stifel Healthcare Conference on November 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119912,"accession_number":"0001404644-25-000088","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene FDA agreement on Rett gene therapy registrational trial; Q4 2025 dosing start","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed FDA discussions on Embolden registrational trial protocol for NGN-401; first participant dosing planned in Q4 2025 across 13 U.S. sites.","New preclinical NHP data shows ICV delivery achieves superior brain biodistribution vs. IT-L at clinically relevant 1E15 vg dose; supports ICV route.","Phase 1/2 data: first 4 participants gained 23 developmental milestones across multiple domains, indicating multi-domain improvement.","ICV and IT-L show comparable peripheral organ transduction; no liver-sparing benefit to IT-L administration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136481,"accession_number":"0001404644-25-000082","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurogene reports Q2 net loss $22M; cash $274.5M, FDA agrees on registrational trial design for Rett gene therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.0M for Q2 2025 vs $18.5M in Q2 2024; R&D expenses $19.4M vs $15.7M.","Cash, cash equivalents and short-term investments $274.5M as of June 30, 2025; runway into early 2028.","FDA provided written agreement on key elements of Embolden registrational trial for NGN-401; sample size refined to propose 20 participants.","Completed dosing in Phase 1/2 NGN-401 trial; last 5 participants dosed in H1 2025; updated clinical data expected H2 2025.","No evidence of HLH/hyperinflammatory syndrome in any NGN-401 participant at 1E15 vg dose level as of press date."],"consensus_eps_estimate":-1.1817,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153641,"accession_number":"0001404644-25-000070","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene announces FDA agreement on registrational trial design for NGN-401 gene therapy in Rett syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA agreed on single-arm, open-label, baseline-controlled design; N=18 proposed; primary endpoint: CGI-I improvement plus gain of developmental milestone.","Phase 1/2 fully enrolled; 5 participants dosed in 1H2025; no HLH/hyperinflammatory syndrome observed at 1E15 vg dose.","First four participants achieved 23 developmental milestones across hand function, communication, and ambulation by 3–15 months.","Cash, cash equivalents & investments of $292.6M as of March 31, 2025; runway extended into early 2028.","Updated efficacy and safety data expected in second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153640,"accession_number":"0001404644-25-000053","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Neurogene shareholders approve equity plan amendments, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendments to 2023 Equity Incentive Plan and ESPP approved; shares from prefunded warrants and convertible preferred counted in automatic share reserve increase.","Elected Sarah B. Noonberg and Robert 'Keith' Woods as Class II directors until 2028; each received >10.3M votes for.","Say-on-pay advisory vote passed with 7.72M for (68.7% of votes cast excluding broker non-votes).","Ratified Deloitte & Touche as independent auditor for FY2025; 99.9% of votes cast in favor.","Quorum of 11.48M shares (80.5% of voting power) present at the June 12, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153639,"accession_number":"0001404644-25-000049","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neurogene posts updated corporate presentation; no material new info disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing reports only that an updated corporate presentation was posted on June 9, 2025.","No financial results, guidance, or operational milestones provided in the filing body.","Exhibit 99.1 referenced but its full content not available in this summary; limited to a header only.","Investors should refer to the presentation directly for any potential updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153638,"accession_number":"0001404644-25-000044","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurogene reports Q1 net loss of $22.6M; cash $292.6M; NGN-401 trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.6M for Q1 2025 vs $16.9M Q1 2024; R&D expenses rose to $17.8M from $13.5M.","Cash, equivalents and short-term investments of $292.6M as of March 31, 2025; runway into H2 2027.","NGN-401 gene therapy for Rett syndrome: registrational trial plan update expected in H1 2025; interim clinical data in H2 2025.","Enrolling additional participants in Phase 1/2 trial; pediatric cohort (age 4-10, N=8) and older cohort (11+, N=3).","Peer-reviewed publication in Science Translational Medicine validating EXACT transgene regulation technology."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153637,"accession_number":"0001404644-25-000029","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Neurogene raises BBA director nomination threshold to 14.9%, exchanges shares for prefunded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BBA director nomination threshold raised from 12.5% to 14.9% of voting common stock via amendment to July 2023 letter agreement.","Exchange agreement: 667,500 common shares swapped for prefunded warrants to buy 667,563 shares at $0.001 exercise price.","Post-exchange: 14,262,066 common shares outstanding; 6,792,559 prefunded warrants outstanding.","Prefunded warrants have 4.99% beneficial ownership limitation, adjustable up to 19.99% with 61 days' notice.","Exchange expected to close April 14, 2025, exempt from registration under Section 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172340,"accession_number":"0001404644-25-000014","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurogene posts FY2024 net loss $75.1M, cash $312.4M, NGN-401 gets EMA PRIME, trial updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $312.4M as of Dec 31, 2024; runway into H2 2027 to support NGN-401 registrational trial and pipeline.","R&D expenses $60.9M in FY2024 (up from $44.4M) on higher Rett trial costs and headcount; net loss $75.1M vs $36.3M prior year.","NGN-401 Phase 1/2 trial: dose fixed at 1E15 vg, age range expanded >11 years; received EMA PRIME designation.","Anticipated milestones: regulatory update on registrational plans in H1 2025; additional interim clinical data in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172339,"accession_number":"0001404644-25-000004","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene posts updated corporate presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated January 2025 posted on Neurogene's website.","No specific financial or operational data from the presentation disclosed in the filing.","Presentation furnished as Exhibit 99.1; contents not reproduced in this excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189346,"accession_number":"0001404644-24-000109","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Neurogene patient dies after high-dose NGN-401; FDA allows trial to continue at lower dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient dosed Nov 5 with 3E15 vg NGN-401 died from hyperinflammatory syndrome linked to high AAV exposure.","FDA permitted Phase 1/2 trial to continue using 1E15 vg dose for pediatric and adolescent/adult cohorts.","Neurogene will incorporate the 1E15 vg dose into future registrational trial design.","This is the same patient previously reported as critical; hyperinflammatory syndrome is rare and life-threatening."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189345,"accession_number":"0001404644-24-000103","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurogene Q3 net loss $20.2M; positive NGN-401 data; $200M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $20.2M vs $14.6M YoY; cash & investments $139M as of Sep 30, 2024.","First 4 NGN-401 participants at 1E15 vg showed consistent improvements; 28-52% RSBQ improvement.","SAE at 3E15 vg dose; FDA allows continued enrollment at 1E15 vg; enrollment paused for protocol revision.","NGN-101 CLN5 Batten program discontinued after RMAT application denied; options being evaluated.","Closed ~$200M private placement extending cash runway into second half of 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":925000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189344,"accession_number":"0001404644-24-000097","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene reports serious hyperinflammatory syndrome in high-dose NGN-401 patient; high-dose cohort halted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient dosed on Nov 5 with 3E15 vg dose developed life-threatening systemic hyperinflammatory syndrome; is in critical condition.","FDA allowed trial to continue with low-dose cohort (1E15 vg); no other treatment-related SAEs to date.","Five participants in 1E15 vg cohort had only mild AEs; no MeCP2 overexpression or ICV procedure-related AEs.","Neurogene paused high-dose enrollment and no longer expects to complete low-dose enrollment in Q4 2024 due to protocol updates.","Company proactively engaged FDA via START program; high-dose cohort permanently discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189343,"accession_number":"0001404644-24-000091","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene reports positive interim efficacy data from low-dose cohort of NGN-401 gene therapy for Rett syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 4 low-dose participants achieved a 2-point improvement on clinician-rated CGI-I scale from baseline.","Caregiver-completed RSBQ scores improved 28–52% from baseline; participants acquired developmental milestones not seen in natural history.","Low-dose NGN-401 well-tolerated with no treatment-related SAEs; emerging SAE noted in a third high-dose participant.","Initiated adolescent/adult cohort (age ≥16) and gained FDA alignment on potency assay and manufacturing scale-up for registrational trial.","Company discontinued CLN5 Batten disease program after RMAT application denial; evaluating options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189342,"accession_number":"0001404644-24-000089","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Neurogene raises $200M in oversubscribed PIPE; funds into H2 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$200M from sale of 1.835M shares at $50/share and 2.165M pre-funded warrants at $49.999 each.","Participating investors include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital, Samsara BioCapital.","Proceeds expected to fund company into second half of 2027 and support NGN-401 registrational study and CMC scale-up.","Closing expected Nov 5, 2024; post-transaction shares outstanding ~21.0M (assuming full warrant exercise).","Company to host webcast Nov 11, 2024 to review Phase 1/2 interim data for NGN-401 Rett syndrome gene therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205843,"accession_number":"0001404644-24-000085","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurogene Q2 net loss $18.5M; NGN-401 gets RMAT and START FDA designations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $153.9M as of June 30, 2024; expected to fund operations into 2H 2026.","Net loss $18.5M in Q2 2024 vs $11.9M in Q2 2023; R&D expenses rose to $15.7M from $10.3M.","NGN-401 for Rett syndrome received RMAT designation and was selected for FDA START Pilot Program.","First patient dosed in high-dose Cohort 2; interim efficacy data from Cohort 1 expected Q4 2024.","Enrollment complete in NGN-101 for CLN5 Batten disease; data and regulatory update in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":925000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205842,"accession_number":"0001404644-24-000083","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene receives FDA RMAT designation for NGN-401 gene therapy in Rett syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["RMAT designation based on preliminary clinical evidence from ongoing Phase 1/2 trial showing potential to address unmet medical needs.","Designation provides Fast Track, Breakthrough Therapy benefits, and eligibility for Accelerated Approval and Priority Review.","NGN-401 previously selected for FDA START Pilot Program; interim low-dose efficacy data expected Q4 2024, high-dose data H2 2025.","CEO notes FDA commitment to expedite development; designation underscores therapeutic potential of NGN-401."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222837,"accession_number":"0001404644-24-000080","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene posts updated corporate presentation; details not provided in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation posted on company website on June 21, 2024.","Presentation is furnished as an exhibit to this 8-K, but its full content is not included in the provided text.","No specific numbers, pipeline updates, or financial figures are available from the excerpt.","Investors should refer to the full presentation on Neurogene's website for material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222836,"accession_number":"0001404644-24-000073","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene doses first patient in high-dose cohort of NGN-401; safety data positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient in Cohort 2 received high-dose NGN-401 in May 2024; well-tolerated to date.","Low-dose cohort (3 patients) shows no new treatment-related adverse events; all AEs mild/Grade 1.","No signs of MeCP2 overexpression toxicity, including in patient with mild genetic variant.","Company expects interim efficacy data from low-dose cohort in Q4 2024.","Neurogene is participating in FDA's START Pilot Program to accelerate NGN-401 development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222835,"accession_number":"0001404644-24-000066","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neurogene shareholders elect both director nominees and approve advisory votes at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cory Freedland and Rachel McMinn elected as Class I directors with ~9.2M votes for each.","Advisory say-on-pay approved: 9,092,990 for, 482,023 against, 5,878 abstain.","Ratification of Deloitte & Touche as auditor for FY2024 passed with 9,826,384 votes for.","Quorum achieved with 9,829,572 shares (76.4% of voting power) present at June 14, 2024 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222834,"accession_number":"0001404644-24-000059","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene's NGN-401 Rett syndrome gene therapy selected for FDA START Pilot Program","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NGN-401 one of only three CBER programs chosen for FDA's START Pilot Program.","START provides enhanced communications with FDA to accelerate development of rare disease therapies.","Phase 1/2 trial of NGN-401 ongoing; favorable safety data from first three patients reported.","Interim efficacy data from the trial expected in Q4 2024.","Company aims to advance NGN-401 toward potential registrational study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222833,"accession_number":"0001404644-24-000054","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurogene Q1 net loss $16.9M; NGN-401 safety positive, on track for efficacy data 4Q24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $169.5M as of March 31, 2024; cash runway into 2H 2026.","R&D expenses $13.5M (up 31% YoY); net loss $16.9M vs $12.3M in Q1 2023.","NGN-401 gene therapy for Rett syndrome well-tolerated; all AEs mild/Grade 1.","Australian regulatory clearance received; interim efficacy data from Cohort 1 expected 4Q 2024.","Advancing early-stage pipeline; another product candidate expected to enter clinic in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222832,"accession_number":"0001404644-24-000049","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene's NGN-401 gene therapy well tolerated in first three Rett syndrome patients; no overexpression toxicity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three pediatric patients (ages 4-7) treated with single ICV dose show mild, transient AEs; no serious adverse events.","No signs of MeCP2 overexpression toxicity in any patient, including one with a mild variant predicted to retain residual MeCP2 expression.","Follow-up ranges from ~3 to ~9 months; data cut-off April 19, 2024.","Interim efficacy data from Cohort 1 expected in Q4 2024; additional data including Cohort 2 in H2 2025.","NGN-401 uses EXACT transgene regulation technology to limit overexpression risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222831,"accession_number":"0001404644-24-000041","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Neurogene amends CSO Stuart Cobb's consulting agreement; sets $440K annual fee, success bonus up to 40%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Stuart Cobb to continue as CSO under amended consulting agreement with Neurogene.","Minimum annual consulting fee of $440,000 paid monthly; eligible for annual success fee of up to 40%.","Termination without cause or for good reason: lump sum of 1.0x annual fee plus pro-rata bonus (non-CIC) or (CIC) includes equity acceleration.","Agreement effective April 19, 2024; replaces prior consulting agreement from December 2018."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222830,"accession_number":"0001404644-24-000029","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene Reports Positive Initial Safety Data from Phase 1/2 Gene Therapy Trial for Rett Syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NGN-401 generally well-tolerated in three patients with multiple months of follow-up.","No treatment-emergent or procedure-related serious adverse events or MeCP2 overexpression toxicity observed.","Data presented at ASGCT Annual Meeting; includes one patient with mild variant predicted to retain residual MeCP2 function.","Company expects interim efficacy readout in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222829,"accession_number":"0001404644-24-000026","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Neurogene enters employment agreements with CEO McMinn and CFO Mikail; base salaries $595k and $515k","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Rachel McMinn gets $595k base salary, 55% target bonus, 12-month severance non-CIC.","CFO Christine Mikail gets $515k base salary, 45% target bonus, 12-month severance non-CIC.","CIC severance: CEO gets 1.5x salary+bonus, CFO 1.25x, plus equity acceleration.","Both eligible for annual equity awards as determined by Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242309,"accession_number":"0001404644-24-000024","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","2.01","9.01"],"status":"ready","headline":"Neurogene reports FY2023 net loss $36.3M; Rett gene therapy trial expanded, cash runway to H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $197.2M at Dec 31, 2023; reverse merger and $95M private placement completed December 2023.","FY2023 net loss $36.3M vs $55.2M prior year; Q4 net income $2.4M from $16.4M bargain purchase gain.","R&D expenses $44.4M (down from $47.5M), G&A $11.2M (up from $9.0M) due to reverse merger costs.","Phase 1/2 NGN-401 Rett syndrome trial expanded with high-dose Cohort 2; interim clinical data expected 4Q24.","Appointed Dr. Julie Jordan as CMO; CLN5 Batten disease trial interim data and regulatory update expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242308,"accession_number":"0001193125-24-056852","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene expands Rett syndrome gene therapy trial, adds high-dose cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 1 expanded from 5 to 8 patients; staggered dosing removed for parallel enrollment.","New Cohort 2 with higher dose (3×10^15 vector genomes) added; first patient dosing expected Q2 2024.","Third patient dosed in Cohort 1; no serious adverse events or overexpression-related toxicity observed.","Interim Cohort 1 data expected Q4 2024; Cohort 2 data expected H2 2025.","Targeted immunosuppression (rituximab, sirolimus) added for Cohort 2 to prevent AAV immune responses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242307,"accession_number":"0001193125-24-041440","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neurogene appoints Donna Cochener as SVP and General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donna Cochener appointed SVP, General Counsel effective February 15, 2024.","Base salary set at $370,000 annually; eligible for annual bonus up to 35% of salary.","Received option grant for 40,000 shares; 25% vests at one year, rest monthly over 36 months.","Prior consulting agreement terminated upon hire; no written employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242306,"accession_number":"0001193125-24-002861","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neurogene reports ~$200M cash; DSMB clears third patient in Rett syndrome trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB cleared third pediatric patient for dosing in NGN-401 Phase 1/2 for Rett syndrome; dosing expected early Q1 2024.","UK MHRA approved CTA for NGN-401, enabling trial expansion beyond US.","Ended 2023 with ~$200M cash; cash runway into 2H 2026.","Plan to report interim Phase 1/2 data for NGN-401 in 4Q 2024 and NGN-101 in 2H 2024; FDA discussions for NGN-101 in 2H 2024.","Extended research collaboration with University of Edinburgh by three years; plan to advance one discovery product into clinic in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259710,"accession_number":"0001193125-23-298152","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["5.07","1.01","2.01","9.01","3.03","5.01","5.02","5.03","5.05","5.08","7.01"],"status":"ready","headline":"Neoleukin completes reverse merger with Neurogene; raises ~$95M PIPE; interim CEO/CFO depart","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Dec 18, 2023: Neoleukin renamed Neurogene Inc.; all Neurogene stock converted at 0.0756:1 exchange ratio.","Pre-closing financing raised ~$95M from 36.9M shares and 24.0M pre-funded warrants. Post-merger shares outstanding: ~16.9M (assuming full exercise).","Pre-merger Neoleukin stockholders received one CVR per share for potential proceeds from legacy asset sales and lease savings.","Donna Cochener (Interim CEO/GC) and Sean Smith (Interim CFO) terminated at closing; entered separation agreements with severance.","Neurogene dosed first two female pediatric Rett syndrome patients in NGN-401 Phase 1/2 trial; no treatment-emergent serious adverse events reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259709,"accession_number":"0001193125-23-289922","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neoleukin faces 3 stockholder suits over Neurogene merger; issues supplemental disclosures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three lawsuits and ten demands received from stockholders challenging the merger and proxy disclosures.","Company denies any legal violations but provides supplemental disclosures to avoid litigation disruption.","Supplemental disclosures amend sections on Transaction Committee composition, valuation DCF, and selected public company analyses.","DCF implied Neurogene equity value of $445M-$560M; selected companies analysis with 20% illiquidity discount used.","Executive officers Sean Smith and Donna Cochener entered post-merger consulting negotiations for transition and CVR matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259708,"accession_number":"0001193125-23-288502","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neoleukin revises CVR agreement with $500K de minimis threshold and unused lease holdback inclusion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revised CVR Agreement adds a $500,000 de minimis threshold for CVR payments; unpaid amounts distributed by June 30, 2029.","100% of unused Lease Negotiation Holdback balance included in Gross Proceeds for CVR payments.","Amendment relates to the pending merger with Neurogene; closing expected under prior merger agreement.","CVR term ends June 30, 2029; payments made in cash or stock at company's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276977,"accession_number":"0001628280-23-032817","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Neoleukin Therapeutics to effect 1-for-5 reverse stock split on Sept 25 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split at 1-for-5 ratio effective 12:01 a.m. ET on Sept 25, 2023; ticker NLTX unchanged, new CUSIP 64049K203.","Purpose: regain compliance with Nasdaq minimum bid price requirement of $1.00 per share.","Outstanding shares reduced from ~44,026,429 to ~8,805,285; no fractional shares, cash paid in lieu.","Authorized shares decreased from 100,000,000 to 20,000,000 per Certificate of Amendment filed with Delaware.","Proportionate adjustments to exercise prices and shares underlying equity awards and pre-funded warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276976,"accession_number":"0001193125-23-188522","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Neoleukin to merge with Neurogene; Neurogene stockholders to own ~84% of combined co.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Neoleukin stockholders will own ~16% of combined company; Neurogene stockholders ~84% on as-converted basis.","Concurrent ~$95M private financing from investors to close immediately before merger.","Closing conditions include Neoleukin net cash >= $60M and Neurogene gross proceeds >= $75M from financing.","Post-merger board of 7 directors: 5 designated by Neurogene, 2 by Neoleukin; CVRs for legacy asset proceeds.","Support agreements from ~77% of Neurogene and ~21% of Neoleukin stockholders; 180-day lock-up on shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294833,"accession_number":"0001628280-23-021819","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neoleukin stockholders approve reverse stock split and elect directors at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors Boyd, Palekar, and Simpson with >17.6M shares for each.","Approved reverse stock split at ratio 1:2 to 1:5, board to set exact ratio within one year.","Approved officer exculpation amendment with 11.6M For vs 8.8M Against (excluding broker non-votes).","Ratified Deloitte & Touche as auditor for FY2023 with 27.0M shares for.","Non-binding advisory vote on executive compensation approved with 13.5M For vs 6.8M Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294832,"accession_number":"0001628280-23-010410","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Neoleukin appoints interim CEO and CFO after Drachman resignation; CMO Patel departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donna Cochener appointed Interim CEO; Sean Smith appointed Interim CFO, effective March 31, 2023.","Dr. Jonathan Drachman resigned as President, CEO and director, effective March 31, 2023 (previously announced March 6).","Cochener receives base salary $450,000; Smith $410,000; annual bonuses and retention bonuses up to $219,375 and $159,167 respectively.","CMO Dr. Priti Patel separated; receives 9 months salary continuation, healthcare, and accelerated vesting of 100,000 options.","Interim officers' severance: 9 months salary plus COBRA; enhanced 15 months lump sum on change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315416,"accession_number":"0001628280-23-007432","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"Neoleukin cuts 70% of workforce, CEO to resign as company seeks strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 70% workforce reduction and re-prioritization to seek strategic alternatives to maximize shareholder value.","Estimated restructuring costs between $2.5M and $3.0M, primarily severance and benefits, with $0.3M non-cash.","CEO Jonathan Drachman resigns as President, CEO and director effective March 31, 2023; no replacement announced.","Severance includes 12-month salary continuation, 3-month target cash bonus, accelerated option vesting of August 2022 grant.","Execution of restructuring expected substantially complete by end of Q2 2023; costs incurred in first half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315415,"accession_number":"0001628280-23-007026","cik":1404644,"company_name":"Neurogene Inc.","ticker":"NGNE","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Neoleukin initiates strategic alternatives review, cuts workforce by 70%, CEO Drachman to step down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged SVB Securities to explore sale, merger, asset divestiture, licensing, or other transaction to maximize shareholder value.","Board approved 70% workforce reduction to preserve cash; completion expected in first half of 2023.","CEO Jonathan Drachman, M.D., stepping down after a short transition period.","No assurance that any transaction will occur or on attractive terms; company will not disclose updates until definitive agreements reached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":431549952.0152586,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-08T23:59:59+00:00|315415"}